Loading clinical trials...

COMPLETED

To Evaluate the Criteria for Renewal of Luteinizing Hormone-Releasing Hormone (LHRH) Analogue Treatment in Prostate Cancer Patients

A Prospective Post Marketing Non Interventional Study to Evaluate the Criteria on Which Renewal of LHRH Analogue Treatment is Made in Patients With Prostate Cancer Locally Advanced or Metastatic.

NCT03017313•Ipsen

View on ClinicalTrials.gov

Summary

The purpose of the study, is to determine the percentage of patients for whom the initial LHRH prescription has been renewed

Eligibility

Age

18 - No limit years

Sex

MALE

Healthy Volunteers

Inclusion Criteria

•Adult men diagnosed of locally advanced or metastatic prostate cancer scheduled to receive androgen deprivation therapy with a 3 or 6 month LHRH analogue including those requiring neo-adjuvant or adjuvant androgen deprivation therapy in association with radiotherapy
•Patients having provided written informed consent
•Patients mentally fit for completing a self-administrated questionnaire

Exclusion Criteria

•Patients participating in another clinical study at the time of inclusion
•Patients with another severe malignant disease
•Life expectancy of less than 12 months
•Patients already treated with a LHRH analogue within the last year

Locations (27)

Hospital A Coruña

A Coruña, Spain

Hospital del Sureste

Arganda, Spain

Hospital San Agustín

Avilés, Spain

Hospital de Txagorritxu

Barakaldo, Spain

Hospital de Basurto

Bilbao, Spain

Hospital Gral. Univ. Santa Lucía

Cartagena, Spain

Hospital Arquitecto Marcide

Ferrol, Spain

Hospital Univ. de Getafe

Getafe, Spain

Hospital de Cabueñes

Gijón, Spain

Hospital Universitario Dr Negrín

Las Palmas de Gran Canaria, Spain

Key Dates

Start Date

July 13, 2017

Primary Completion Date

June 14, 2021

Completion Date

June 14, 2021

Last Updated

June 24, 2021

Enrollment

510

ACTUAL participants

Conditions

Prostate Cancer

Interventions

LHRH analogues

DRUG

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+29 more

View study

RECRUITINGPHASE2

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

NCT05691465

Metastatic Prostate Adenocarcinoma With Neuroendocrine DifferentiationMetastatic Prostate Neuroendocrine Carcinoma+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 24, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

To Evaluate the Criteria for Renewal of Luteinizing Hormone-Releasing Hormone (LHRH) Analogue Treatment in Prostate Cancer Patients

Inclusion Criteria

Exclusion Criteria

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC